Halozyme Therapeutics (HALO) 9.73 $HALO
Halozyme to Host second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Aug 04, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2014.
FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency
M2 - Mon Aug 04, 6:32AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
PR Newswire - Tue Jul 22, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
2 Small-Cap Stocks Hedge Funds Love
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jul 17, 4:15PM CDT
Credit : Dr. Partha Sarathi Sahana , Flickr. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some promising small-caps companies to your portfolio but don't have the time or...
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
PR Newswire - Thu Jul 10, 6:20AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:
New Drug Applications, Agreements, Launches, and Appointments - Analyst Notes on Curis, Enzo Biochem, AGTC, Halozyme and Magellan Health
PR Newswire - Wed Jul 02, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Curis, Inc. (NASDAQ: CRIS), Enzo Biochem, Inc. (NYSE: ENZ), Applied Genetic Technologies Corp (NASDAQ: AGTC), Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Magellan Health Inc (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4361-100free.
Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme
PR Newswire - Wed Jun 25, 7:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin® SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche's oncology products using Halozyme's patented EnhanzeTM (recombinant human hyaluronidase) technology to be launched in Europe.
Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference
PR Newswire - Tue Jun 17, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY, on Tuesday, June 24, 2014 at 2:30 p.m. ET/11:30 a.m. PT. David Ramsay, Chief Financial Officer, will provide a corporate overview.
Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions
PR Newswire - Sun Jun 15, 2:00PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th Scientific Sessions of the American Diabetes Association in San Francisco. The CONSISTENT 1 trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S. Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes (T1DM) receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment. Data reported in the presentation show that the study's primary endpoint of non-inferiority for A1C at six months between the use of Hylenex and the new formulation of Hylenex in comparison to no pre-treatment was met. In addition to other trial data, the poster also presents data indicating that there was a potential reduction in the rate of hypoglycemic events associated with the use of the Hylenex formulations in comparison to no pre-treatment.
Swing Trade Ideas for Friday June 13: First Majestic Silver, Clovis, More
at The Street - Fri Jun 13, 11:22AM CDT
First Majestic Silver, Clovis Oncology and Halozyme Therapeutics are our big swing trades for today. So how should investors buy and sell?AG, CLVS, DWA, HALO
Why Halozyme Therapeutics Inc. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 12, 1:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Halozyme Therapeutics , a developer of...
Nasdaq stocks posting largest percentage increases
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Upgrade Alert for Halozyme Therapeutics (HALO)
Comtex SmarTrend(R) - Thu Jun 12, 7:01AM CDT
Halozyme Therapeutics (NASDAQ:HALO) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $9.39 on volume of 1.6 million shares, below average daily volume of 2.2 million. Over the past year, Halozyme Therapeutics has traded in a range of $3.86 to $18.18 and closed yesterday at $9.39, 143% above that low. The 200-day and 50-day moving averages have moved 0.25% higher and 2.2% lower over the past week, respectively.
Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning
at The Street - Thu Jun 12, 7:01AM CDT
About Halozyme Therapeutics, UBS:said 'We like the positioning from here. Upgrading...on pipeline potential and risk/reward.'
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Jun 11, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma
PR Newswire - Fri Jun 06, 7:10AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the day 0.59% higher at 16,836.11, and the S&P 500 closed at 1,940.46, up 0.65%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 695.40, up 0.16%, and the index has advanced 3.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Medivation Inc. (NASDAQ: MDVN), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free technical research on HALO, MDVN, ACHN and ALXN can be downloaded upon signing up at:
Halozyme to Host second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Aug 04, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2014.
FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency
M2 - Mon Aug 04, 6:32AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
PR Newswire - Tue Jul 22, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
2 Small-Cap Stocks Hedge Funds Love
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jul 17, 4:15PM CDT
Credit : Dr. Partha Sarathi Sahana , Flickr. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some promising small-caps companies to your portfolio but don't have the time or...
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
PR Newswire - Thu Jul 10, 6:20AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:
New Drug Applications, Agreements, Launches, and Appointments - Analyst Notes on Curis, Enzo Biochem, AGTC, Halozyme and Magellan Health
PR Newswire - Wed Jul 02, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Curis, Inc. (NASDAQ: CRIS), Enzo Biochem, Inc. (NYSE: ENZ), Applied Genetic Technologies Corp (NASDAQ: AGTC), Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Magellan Health Inc (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4361-100free.
Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme
PR Newswire - Wed Jun 25, 7:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin® SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche's oncology products using Halozyme's patented EnhanzeTM (recombinant human hyaluronidase) technology to be launched in Europe.
Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference
PR Newswire - Tue Jun 17, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY, on Tuesday, June 24, 2014 at 2:30 p.m. ET/11:30 a.m. PT. David Ramsay, Chief Financial Officer, will provide a corporate overview.
Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions
PR Newswire - Sun Jun 15, 2:00PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th Scientific Sessions of the American Diabetes Association in San Francisco. The CONSISTENT 1 trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S. Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes (T1DM) receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment. Data reported in the presentation show that the study's primary endpoint of non-inferiority for A1C at six months between the use of Hylenex and the new formulation of Hylenex in comparison to no pre-treatment was met. In addition to other trial data, the poster also presents data indicating that there was a potential reduction in the rate of hypoglycemic events associated with the use of the Hylenex formulations in comparison to no pre-treatment.
Swing Trade Ideas for Friday June 13: First Majestic Silver, Clovis, More
at The Street - Fri Jun 13, 11:22AM CDT
First Majestic Silver, Clovis Oncology and Halozyme Therapeutics are our big swing trades for today. So how should investors buy and sell?AG, CLVS, DWA, HALO
Why Halozyme Therapeutics Inc. Shares Surged
Sean Williams, The Motley Fool - Motley Fool - Thu Jun 12, 1:34PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Halozyme Therapeutics , a developer of...
Nasdaq stocks posting largest percentage increases
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Upgrade Alert for Halozyme Therapeutics (HALO)
Comtex SmarTrend(R) - Thu Jun 12, 7:01AM CDT
Halozyme Therapeutics (NASDAQ:HALO) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $9.39 on volume of 1.6 million shares, below average daily volume of 2.2 million. Over the past year, Halozyme Therapeutics has traded in a range of $3.86 to $18.18 and closed yesterday at $9.39, 143% above that low. The 200-day and 50-day moving averages have moved 0.25% higher and 2.2% lower over the past week, respectively.
Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning
at The Street - Thu Jun 12, 7:01AM CDT
About Halozyme Therapeutics, UBS:said 'We like the positioning from here. Upgrading...on pipeline potential and risk/reward.'
Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 11, 11:16AM CDT
The week so far has been highly eventful
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Jun 11, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 07, 12:05PM CDT
With the SPDR S&P Biotech Index up 25% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma
PR Newswire - Fri Jun 06, 7:10AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the day 0.59% higher at 16,836.11, and the S&P 500 closed at 1,940.46, up 0.65%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 695.40, up 0.16%, and the index has advanced 3.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Medivation Inc. (NASDAQ: MDVN), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free technical research on HALO, MDVN, ACHN and ALXN can be downloaded upon signing up at:
